The PKMYT1 antagonist lunresertib (RP-6306) synergized with gemcitabine, significantly reducing the viability of ER+ breast cancer cells resistant to ET and palbociclib, even in the absence of activated p53 [83]. Here, ESR1 is linked to breast cancer.